Cryoport price target raised to $17 from $15 at BTIG

BTIG raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps a Buy rating on the shares. The firm is citing the company’s Q1 earnings beat and guidance raised, with solid market demand seen across all segments as the cell and gene therapy market comes back. While the management has noted that there is some uncertainty in the global macro environment, BTIG believes that the pharma environment continues to improve, demand is picking up, and Cryoport is turning the corner, the analyst tells investors in a research note.